What should prescribers and pharmacies do first when adopting e-prescribing for controlled substances?

The first step is to confirm that both the prescriber workflow and the pharmacy system meet DEA certification requirements. Next, organisations should complete identity proofing for prescribers and enforce two factor authentication before any controlled substance order is signed. That sequence reduces implementation risk and helps avoid a compliant design being undermined by an incomplete rollout.

What to do before the first controlled-substance prescription goes live

Start with the two control planes that determine whether the program is actually deployable: the prescriber workflow and the pharmacy system. E-prescribing for controlled substances is not “turned on” by policy alone, it has to be supported by systems that meet DEA certification requirements, and by prescriber identity proofing plus two factor authentication before a controlled substance order can be signed.

That sequence matters because it prevents a technically approved workflow from being launched with a weak trust foundation. If the certifying controls are not in place first, the program can fail at the point of signature, verification, or dispense, which creates avoidable implementation friction and compliance risk.

Why certification comes before enrollment and signing

The DEA certification check is the gate that tells you whether the workflow is eligible to handle controlled substances at all. For prescribers, that means the signing path, device access, and authentication workflow must be acceptable before you rely on it in production. For pharmacies, the receiving and processing system must also be ready, because a one-sided rollout can create a compliant sender paired with an unready receiver.

This is why the first implementation question is not “who has logged in?” but “are both ends of the transaction certified and aligned?” In practice, that means validating vendor configuration, workflow ownership, and any dependency that could break signature acceptance or order routing once controlled-substance traffic starts.

How identity proofing and two factor authentication fit the rollout

After certification is confirmed, the next control step is prescriber identity proofing followed by two factor authentication. Identity proofing establishes that the prescriber is the right person before credentials are relied on for controlled-substance signing, while two factor authentication raises the bar for account takeover, shared device abuse, and stolen password reuse.

This sequence is important because the signing event is the security boundary, not the registration event. If identity proofing is weak or if authentication is only partially deployed, the prescription channel can appear operational while still being vulnerable to misuse, impersonation, or unauthorized controlled-substance orders.

What a safe first rollout looks like in practice

A sound first rollout uses a narrow scope, with the certified prescriber workflow, the certified pharmacy workflow, and the required authentication path all proven together before broad go-live. That gives teams one place to verify whether the transaction can be created, signed, transmitted, received, and processed without a compensating manual workaround.

It also gives operations a clean cutover point. If a prescriber group, location, or pharmacy chain is not ready, the answer is to hold that population back rather than creating exceptions that erode the control model on day one.

Risk and Threat Considerations

E-prescribing for controlled substances concentrates trust into a small number of workflows, so rollout mistakes can have immediate security and compliance impact. The main risk is not just a broken transaction, but an authorized-looking transaction signed by an account that was not adequately proven or protected.

Failure mechanism: A prescriber or pharmacy is brought live before certification, identity proofing, or two factor authentication is fully effective, which can leave the controlled-substance path exposed to account misuse, failed order acceptance, or control bypass through interim workarounds.

Impact: Controlled-substance orders may be delayed, rejected, or improperly authorized, and the organisation can inherit both operational disruption and a higher risk of fraudulent or unauthorized prescribing.

Standards & Framework Alignment

This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.

OWASP Non-Human Identity Top 10 addresses the attack and risk surface, while NIST SP 800-53 Rev 5 sets the governance and control requirements practitioners need to meet.

Framework	Control / Reference	Relevance
NIST SP 800-53 Rev 5	IA-8 — Identification and Authentication (Non-Organizational Users)	Prescriber identity proofing and authentication are central to controlled-substance e-prescribing.
	IA-5 — Authenticator Management	Two factor authentication depends on secure lifecycle control of authenticators.
	IA-2 — Identification and Authentication (Organizational Users)	The prescriber workflow must authenticate approved clinical users before signing orders.
Recommendation — Require strong proofing and authentication before allowing controlled-substance signing. Manage authenticators so e-prescribing access cannot be signed with weak or stale credentials. Enforce strong user authentication on the prescribing workflow before controlled-substance go-live.
OWASP Non-Human Identity Top 10	NHI-04 — Insecure Authentication	The workflow includes system and service access that must not rely on weak authentication paths.
Recommendation — Eliminate weak authentication paths before enabling controlled-substance workflow access.

Practitioner Guidance

What to prioritise: Verify the end-to-end signing path before scaling out. The first acceptable state is not “the software is installed,” it is “the prescriber can be positively verified, the pharmacy can receive the order, and the controlled-substance transaction completes under the required authentication controls.”

What to verify: Test the full chain for each initial prescriber and pharmacy cohort, including certification status, identity proofing evidence, two factor enforcement, and exception handling. If any step requires a temporary bypass, treat that as a rollout blocker rather than an acceptable launch compromise.

Practitioner takeaway: For controlled substances, the safest first move is to prove the workflow and the trust chain together, then expand only after both the prescriber and pharmacy sides are demonstrably ready.